News + Filings Transactions
|
Nolan Sean P.
| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/16/2023 | Taysha Gene Therapies, Inc. | | Purchase | Common Stock | 444.4k | $0.90 | $400k | See Footnote | 08/16/2023 |
| 05/16/2023 | Ventas, Inc. | VTR | Grant | Common Stock | 3.8k | $45.63 | $175k | | 05/16/2023 |
| 12/30/2022 | Taysha Gene Therapies, Inc. | | Grant | Stock Option (right to buy) | 1.1M | $2.26 | $2.5M | | 12/30/2022 |
| 06/17/2022 | Taysha Gene Therapies, Inc. | | Grant | Stock Option (right to buy) | 15.5k | $2.81 | $43.6k | | 06/17/2022 |
| 04/27/2022 | Ventas, Inc. | VTR | Grant | Common Stock | 3.1k | $57.25 | $175k | | 04/27/2022 |
| 06/17/2021 | Taysha Gene Therapies, Inc. | | Grant | Stock Option (right to buy) | 15.5k | $25.04 | $388.1k | | 06/17/2021 |
| 05/25/2021 | Ventas, Inc. | VTR | Grant | Common Stock | 3.2k | $0.00 | $0 | | 05/25/2021 |
| 05/20/2021 | Taysha Gene Therapies, Inc. | | Purchase | Common Stock | 1.2k | $22.35 | $26.1k | | 05/20/2021 |
| 09/28/2020 | Taysha Gene Therapies, Inc. | | Conversion | Series B Preferred Stock | 1.5k | $0.00 | $0 | See Footnote | 09/28/2020 |
| 09/28/2020 | Taysha Gene Therapies, Inc. | | Conversion | Common Stock | 1.1M | $0.00 | $0 | See Footnote | 09/28/2020 |
| 09/28/2020 | Taysha Gene Therapies, Inc. | | Conversion | Common Stock | 1.6k | $0.00 | $0 | See Footnote | 09/28/2020 |
| 09/28/2020 | Taysha Gene Therapies, Inc. | | Conversion | Series A Preferred Stock | 1000k | $0.00 | $0 | See Footnote | 09/28/2020 |
| 09/23/2020 | Taysha Gene Therapies, Inc. | | Grant | Stock Option (right to buy) | 31k | $20.00 | $620k | | 09/23/2020 |
| 05/18/2020 | Ventas, Inc. | VTR | Grant | Common Stock | 5.4k | $0.00 | $0 | | 05/18/2020 |
| 05/05/2020 | Neoleukin Therapeutics, Inc. | AQXP | Grant | Stock Option (Right to Buy) | 25k | $12.84 | $321k | | 05/05/2020 |
| 10/10/2019 | Neoleukin Therapeutics, Inc. | AQXP | Grant | Stock Option (right to buy) | 22k | $2.82 | $62k | | 10/10/2019 |
| 07/26/2019 | Ventas, Inc. | VTR | Grant | Common Stock | 2.1k | $67.03 | $142.8k | | 07/26/2019 |
| 05/15/2018 | AveXis, Inc. | AVXS | Disposition | Stock Option (Right to Buy) | 110k | $42.61 | $4.7M | | 05/15/2018 |
| 05/15/2018 | AveXis, Inc. | AVXS | Disposition | Stock Option (Right to Buy) | 96k | $77.24 | $7.4M | | 05/15/2018 |
| 05/15/2018 | AveXis, Inc. | AVXS | Disposition | Stock Option (Right to Buy) | 44k | $133.80 | $5.9M | | 05/15/2018 |
| 05/15/2018 | AveXis, Inc. | AVXS | Disposition | Common Stock | 11k | $0.00 | $0 | | 05/15/2018 |
| 05/15/2018 | AveXis, Inc. | AVXS | Disposition | Stock Option (Right to Buy) | 728.3k | $15.94 | $11.6M | | 05/15/2018 |
| 05/07/2018 | Neoleukin Therapeutics, Inc. | AQXP | Grant | Stock Option (Right to Buy) | 15k | $13.10 | $196.5k | | 05/07/2018 |
| 03/13/2018 | AveXis, Inc. | AVXS | Grant | Common Stock | 11k | $0.00 | $0 | | 03/13/2018 |
| 03/13/2018 | AveXis, Inc. | AVXS | Grant | Employee Stock Option (Right to Buy) | 44k | $133.80 | $5.9M | | 03/13/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Sale | Common Stock | 1.1k | $131.86 | $145k | | 03/07/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Exercise | Employee Stock Option (Right to Buy) | 10k | $15.94 | $159.4k | | 03/07/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Sale | Common Stock | 400 | $126.65 | $50.7k | | 03/07/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Sale | Common Stock | 700 | $127.65 | $89.4k | | 03/07/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Sale | Common Stock | 2.4k | $128.65 | $308.8k | | 03/07/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Sale | Common Stock | 4.8k | $129.66 | $622.4k | | 03/07/2018 |
| 03/07/2018 | AveXis, Inc. | AVXS | Sale | Common Stock | 600 | $130.78 | $78.5k | | 03/07/2018 |
| 05/10/2017 | AveXis, Inc. | AVXS | Grant | Employee Stock Option (Right to Buy) | 96k | $77.24 | $7.4M | | 05/10/2017 |
| 05/08/2017 | Neoleukin Therapeutics, Inc. | AQXP | Grant | Stock Option (Right to Buy) | 9k | $13.74 | $123.7k | | 05/08/2017 |
| 06/20/2016 | AveXis, Inc. | AVXS | Grant | Employee Stock Option (Right to Buy) | 110k | $42.61 | $4.7M | | 06/20/2016 |
|